A carregar...
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
Regorafenib, a novel multikinase inhibitor, has recently demonstrated overall survival benefits in metastatic colorectal cancer (CRC) patients. Our study aimed to gain further insight into the molecular mechanisms of regorafenib and to assess its potential in combination therapy. Regorafenib was tes...
Na minha lista:
| Publicado no: | Int J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BlackWell Publishing Ltd
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4277327/ https://ncbi.nlm.nih.gov/pubmed/24347491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.28669 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|